Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 11/20 | 0.55 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.53 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | AXL | P30530 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19476341 | 0.81 | IGF1R (0.66) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL3203410 | 0.80 | IGF1R (0.55) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL19476861 | 0.79 | EHMT2 (0.74) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL19462482 | 0.79 | EHMT2 (0.77) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL30367701 | 0.79 | EHMT2 (0.77) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL19476364 | 0.79 | EHMT2 (0.71) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL13485390 | 0.78 | IGF1R (0.53) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL19476383 | 0.78 | EHMT2 (0.76) | BRD4IGF1REGFREHMT2EHMT1 | |
| SCHEMBL28540768 | 0.78 | EGFR (0.54) | BRD4CSF1REGFRAXLERBB2 | |
| SCHEMBL30213684 | 0.78 | EGFR (0.54) | BRD4CSF1REGFRAXLERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-2121634-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SuperGen, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | JAK2, JAK1, IRAK4 | BRD4 2018/4885CSF1R 820/4885IGF1R 1339/4885 |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | BRD4 251/4885CSF1R 1305/4885IGF1R 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.